Bio & CV

Jillian M. Hagel, BSc. MSc. PhD.
Scientist & Artist
Calgary, Alberta
Canada

Personal Statement

I am a biochemist and artist with over 25 years of experience combining scientific research in the plant natural products domain with visual expression on canvas. I am equally at ease in the laboratory as in my art studio, which both serve as venues for learning, discovery, and observation. My entrepreneurial spirit has underpinned several ventures, including the co-founding of two biotechnology companies (Epimeron Inc., now Willow Biosciences Inc., WLLW.TO; MagicMed Industries Inc., now Enveric Biosciences, Inc., NASDAQ:ENVB) and my concomitant foray into an art career.

My scientific background has informed my interests as an artist. My paintings explore humanity’s relationship with plants, including a more than 6000-year history with opium poppy, our political and personal connections with cannabis, our use of henbane and nightshade in magic and seduction, and the hallucinogenic ointments used by witches to fly on their broomsticks. While I have experience in several media, I largely deploy oil or watercolours using traditional techniques.

Education & Coursework

InstitutionDEGREE/DOMAINCompletion DateFIELD OF STUDY
University of CalgaryBSc.06/00Biochemistry
University of CalgaryMSc.12/04Biochemistry
University of CalgaryPhD.12/10Biochemistry
University of CalgaryCVD.In progressVisual Design
University of CalgaryContinuing Ed. (Course, ART109)09/04Acrylics (I)
University of CalgaryContinuing Ed. (Course, ART116)10/04Acrylics (II)
University of CalgaryContinuing Ed. (Course, ART108)09/12Watercolour

Experience

DatesPosition
2010 – 2020Active member, Green Palette Arts, Calgary (Oils, Watercolour, Acrylics)
2010 – 2015Postdoctoral Fellow, University of Calgary
2014 – 2019Chief Operational Officer, Epimeron Inc. (Co-founder)
2015 – 2019Research Associate, University of Calgary
2016 – 2019Chief Operational Officer, Sertürner, Inc. (Co-founder)
2019 – 2020Vice President, Willow Biosciences
2019 – presentVisiting Scientist, University of Calgary
2020 – 2021Chief Operational Officer, MagicMed Industries Inc. (Co-founder)
2021 – 2022Chief Technology Officer, Enveric Biosciences Inc.
2022 – presentVice President, Enveric Biosciences Inc.

Awards

YearAward
1999Alberta Heritage Foundation Undergraduate Student Research Award
1999NSERC Undergraduate Student Research Award
2002 – 2003Alberta Graduate Student Scholarship
2005 – 2009Alberta Ingenuity Fund Graduate Student Scholarship
2008Queen Elizabeth II Graduate Scholarship
2010Gene R. Huber Doctoral Thesis Award, Department of Biological Sciences
2012Genome Canada Young Investigator Award

Funded Grants (Co-Investigator)

DatesGrant
2019 – 2021Genome Alberta Applied Agriculture Genomics Program, $250,000

Publications (Artwork Featured in Scientific Papers)

  • Li, G., Facchini, P.J. (2024) New Frontiers in the biosynthesis of psychoactive specialized metabolites. Current Opinion in Plant Biology 82:102626. https://doi.org/10.1016/j.pbi.2024.102626
  • Hagel, J.M., Facchini, P.J. (2013) Benzylisoquinoline alkaloid metabolism: a century of discovery and a brave new world. Plant Cell Physiology 54, 647. https://doi.org/10.1093/pcp/pct020
  • Facchini, P.J., Bohlmann, J., Ro, D.K., Page, J.E., Covello, P.S., De Luca, V., Mahadevan, K., Sensen, C.W., Storms, R., Martin, V.J.J. (2012) Synthetic biosystems for the production of high-value plant metabolites. Trends in Biotechnology 30, 127. https://doi.org/10.1016/j.tibtech.2011.10.001
  • Hagel, J.M., Krizevski, R., Marsolais, F., Lewinsohn, E., Facchini, P.J. (2012) Biosynthesis of amphetamine analogues in plants. Trends in Plant Science 17, 404. https://doi.org/10.1016/j.tplants.2012.03.004
  • Hagel, J.M., Yeung, E.C., Facchini, P.J. (2008) Got milk? – The secret life of laticifers. Trends in Plant Sciences 13, 631. https://doi.org/10.1016/j.tplants.2008.09.005

Publications (Peer-Reviewed Scientific Papers)

  • Hagel JM, Chang L, Li J, Chen X, Yu L, Gallant JA, Facchini PJ (2025) Bioproduction of a large-scale library of tryptamine derivatives for neuropsychiatric drug screening. ACS Chemical Biology 20, 1212
  • Carr SC, Rehman F, Hagel JM, Chen X, Ng KKS, Facchini PJ (2024) Two ubiquitous aldo-keto reductases in the genus Papaver support a patchwork model for morphine pathway evolution. Communications Biology 7, 1410
  • Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press DJ, Cook SG, Sharma G, Dhananjaya D, Jensen G, Lee JB, Cai C, Gallant JA, Bains J, Tucker JE, Facchini PJ (2024) Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders. Journal of Medicinal Chemistry 67, 1024
  • Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, Press DJ, Raithatha SA, Hagel JM, Facchini PJ (2023) A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines. Journal of Biological Chemistry 299:105231
  • Ozber N, Yu L, Hagel JM, Facchini PJ (2023) Strong feedback inhibition of key enzymes in the morphine biosynthetic pathway from opium poppy detectable in engineered yeast. ACS Chemical Biology 18, 419
  • Ozber N, Carr SC, Morris JS, Liang S, Watkins JL, Caldo KM, Hagel JM, Ng KKS, Facchini PJ (2022) Alkaloid binding to opium poppy major latex proteins triggers structural modification and functional aggregation. Nature Communications 13, 6768
  • Menéndez-Perdomo IM, Hagel JM, Facchini PJ (2021) Benzylisoquinoline alkaloid analysis using high-resolution Orbitrap LC-MSn. Journal of Mass Spectrometry 56, e4683
  • Chen R, Chen X, Hagel JM, Facchini PJ (2020) Virus-Induced Gene Silencing to investigate alkaloid biosynthesis in opium poppy. Methods in Molecular Biology 2172, 75

Selected Patents

  • Hagel, J.M., Facchini, P.J., Ling, C.C. Carboxylated psilocybin derivatives and methods of using. US Patent No. 11,752,130 B2. Enveric Biosciences Canada Inc. Issued Sept. 12, 2023
  • Hagel, J.M., Matinkhoo, K., Facchini, P.J. C4-Carbonothiolate-substituted tryptamine derivatives and methods of using. US Patent No. 11,707,447 B1. Enveric Biosciences Canada Inc. Issued July 25, 2023
  • Hagel, J.M., Facchini, P.J., Ling, C.C. Aldehyde and Ketone Derivatives of Psilocybin and Methods of Using. US Patent Application No. 17/951,594. Enveric Biosciences Canada Inc. Notice of Allowance October 2, 2023
  • Hagel JM, Facchini PJ (2020) Halogenated Psilocybin Derivatives and Methods of Using (#1) (USPTO No. 63/047,662)
  • Hagel JM, Facchini PJ (2020) Hydroxylated Psilocybin Derivatives and Methods of Using (#1) (USPTO No. 63/063,748)
  • Facchini PJ, Hagel JM (2016) Methods and compositions for making ephedrine and related alkaloid compounds (PCT/CA2016/050730)
Scroll to Top